title: Serendipity and new drugs for infectious disease.
abstract: Serendipity, in various shades of semantic legitimacy, is abundantly evident in the history of the chemotherapy of infectious disease. We may be on the threshold of a new era of rational drug design, but most medications for infectious diseases have arisen, and continue to arise, from chance observation, clinical experience, and the empirical search for substances active against pathogens. Chance does not produce drugs; but where chance has played a pivotal role in drug discovery, the event may be considered serendipitous to a greater or lesser degree. In a deliberate search for new drugs, it is often difficult to assess the degree to which any resulting discovery is serendipitous, and the usefulness of the term becomes debatable. Many therapeutic advances emerge from research involving animals, and a triggering "happy accident" may reside in the most basic aspects of animal care or in the most arcane knowledge of animals. The examples discussed in this article deal mostly with parasitic disease and the use of animal models in the discovery of antiparasitic agents. In this area, as in others, chance has laid the groundwork for scientific advancement and practical benefit. Although the applicability of the word serendipity to drug discovery may often be uncertain, the role played by chance should be recognized and welcomed.
authors.affiliation: Parasitology, Merck & Co., Inc., Rahway, NJ, USA.
authors.forename: William C
authors.initials: WC
authors.lastname: Campbell
mesh_terms: D000818:Animals; D000830:Animals, Laboratory; D000871:Anthelmintics; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D012107:Research Design
chemical_list: D000871:Anthelmintics